264 related articles for article (PubMed ID: 21182095)
1. IL-17 production by γδ T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette-Guérin treatment against bladder cancer.
Takeuchi A; Dejima T; Yamada H; Shibata K; Nakamura R; Eto M; Nakatani T; Naito S; Yoshikai Y
Eur J Immunol; 2011 Jan; 41(1):246-51. PubMed ID: 21182095
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of recombinant Bacille Calmette-Guérin secreting interleukin-15-Ag85B fusion protein against bladder cancer.
Takeuchi A; Eto M; Tatsugami K; Shiota M; Yamada H; Kamiryo Y; Dejima T; Kashiwagi E; Kiyoshima K; Inokuchi J; Takahashi R; Yokomizo A; Ohara N; Yoshikai Y
Int Immunopharmacol; 2016 Jun; 35():327-331. PubMed ID: 27093372
[TBL] [Abstract][Full Text] [Related]
3. Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2.
Yamada H; Matsumoto S; Matsumoto T; Yamada T; Yamashita U
J Urol; 2000 Aug; 164(2):526-31. PubMed ID: 10893638
[TBL] [Abstract][Full Text] [Related]
4. The fibronectin attachment protein of bacillus Calmette-Guerin (BCG) mediates antitumor activity.
Sinn HW; Elzey BD; Jensen RJ; Zhao X; Zhao W; Ratliff TL
Cancer Immunol Immunother; 2008 Apr; 57(4):573-9. PubMed ID: 17786441
[TBL] [Abstract][Full Text] [Related]
5. Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells.
Lattime EC; Gomella LG; McCue PA
Cancer Res; 1992 Aug; 52(15):4286-90. PubMed ID: 1638541
[TBL] [Abstract][Full Text] [Related]
6. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
[TBL] [Abstract][Full Text] [Related]
7. Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model.
Yuasa T; Sato K; Ashihara E; Takeuchi M; Maita S; Tsuchiya N; Habuchi T; Maekawa T; Kimura S
Cancer Immunol Immunother; 2009 Apr; 58(4):493-502. PubMed ID: 18682944
[TBL] [Abstract][Full Text] [Related]
8. Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer.
Bockholt NA; Knudson MJ; Henning JR; Maymí JL; Weady P; Smith GJ; Eisenbraun MD; Fraser JD; O'Donnell MA; Luo Y
J Urol; 2012 Jun; 187(6):2228-35. PubMed ID: 22503050
[TBL] [Abstract][Full Text] [Related]
9. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung.
Okamoto Yoshida Y; Umemura M; Yahagi A; O'Brien RL; Ikuta K; Kishihara K; Hara H; Nakae S; Iwakura Y; Matsuzaki G
J Immunol; 2010 Apr; 184(8):4414-22. PubMed ID: 20212094
[TBL] [Abstract][Full Text] [Related]
10. Corynebacterium parvum- and Mycobacterium bovis Bacillus Calmette and Guerin-induced granuloma formation in mice lacking CD4 and CD8.
Senaldi G; Shaklee CL; Mak TW; Ulich TR
Cell Immunol; 1999 May; 193(2):155-61. PubMed ID: 10222057
[TBL] [Abstract][Full Text] [Related]
11. Contribution of alpha/beta and gamma/delta T lymphocytes to immunity against Mycobacterium bovis bacillus Calmette Guérin: studies with T cell receptor-deficient mutant mice.
Ladel CH; Hess J; Daugelat S; Mombaerts P; Tonegawa S; Kaufmann SH
Eur J Immunol; 1995 Mar; 25(3):838-46. PubMed ID: 7705416
[TBL] [Abstract][Full Text] [Related]
12. Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guérin and its correlation with Bacillus Calmette-Guérin viability and natural killer cell activity.
Shapiro A; Ratliff TL; Oakley DM; Catalona WJ
Cancer Res; 1983 Apr; 43(4):1611-5. PubMed ID: 6339040
[TBL] [Abstract][Full Text] [Related]
13. Infection of Mycobacterium bovis bacillus Calmette-Guérin in antibody-mediated gamma delta T-cell-depleted mice.
Nabeshima S; Hiromatsu K; Matsuzaki G; Mukasa A; Takada H; Yoshida S; Nomoto K
Immunology; 1995 Feb; 84(2):317-21. PubMed ID: 7751009
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer.
Yu DS; Lee CF; Hsieh DS; Chang SY
Urology; 2004 Mar; 63(3):596-601. PubMed ID: 15028475
[TBL] [Abstract][Full Text] [Related]
15. Mycobacterium bovis bacillus Calmette-Guérin vaccination mobilizes innate myeloid-derived suppressor cells restraining in vivo T cell priming via IL-1R-dependent nitric oxide production.
Martino A; Badell E; Abadie V; Balloy V; Chignard M; Mistou MY; Combadière B; Combadière C; Winter N
J Immunol; 2010 Feb; 184(4):2038-47. PubMed ID: 20083674
[TBL] [Abstract][Full Text] [Related]
16. CD4+ T cells are required for antigen-specific recruitment of neutrophils by BCG-immune spleen cells.
Appelberg R
Immunology; 1992 Mar; 75(3):414-9. PubMed ID: 1374053
[TBL] [Abstract][Full Text] [Related]
17. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
[TBL] [Abstract][Full Text] [Related]
18. Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin.
Ratliff TL; Palmer JO; McGarr JA; Brown EJ
Cancer Res; 1987 Apr; 47(7):1762-6. PubMed ID: 3545453
[TBL] [Abstract][Full Text] [Related]
19. A possible mechanism of intravesical BCG therapy for human bladder carcinoma: involvement of innate effector cells for the inhibition of tumor growth.
Higuchi T; Shimizu M; Owaki A; Takahashi M; Shinya E; Nishimura T; Takahashi H
Cancer Immunol Immunother; 2009 Aug; 58(8):1245-55. PubMed ID: 19139883
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses.
Suttmann H; Riemensberger J; Bentien G; Schmaltz D; Stöckle M; Jocham D; Böhle A; Brandau S
Cancer Res; 2006 Aug; 66(16):8250-7. PubMed ID: 16912205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
